MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2026.128208

Медицинская библиотека · Vaccine · 2026

Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.

Vattoth Ahamed Lazim, Hayney Mary S, Forati Amir Masoud, Warren Brandy, Kalkeri Raj, Cai Miranda R, Cai Zhaohui, Zhu MingZhu, Cloney-Clark Shane, Plested Joyce S, Parajuli Sandesh, Caldera Freddy

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Immunosuppressed individuals are at increased risk of coronavirus disease (COVID-19). Although mRNA vaccines have shown efficacy in these populations, data on protein-based vaccines remain limited. We evaluated the immunogenicity and safety of Novavax COVID-19 vaccine (NVX-CoV2601) in immunosuppressed patients.

METHODS

This single-center, prospective ARMOR study included adults with inflammatory bowel disease (IBD) or solid organ transplant recipients receiving immunosuppressive therapy who had received ≥3 prior COVID-19 vaccine doses. Participants received one NVX-CoV2601 booster with follow-up at one and six months. The primary outcome was change in humoral immunogenicity from baseline to one month post-vaccination.

RESULTS

Twenty-one immunosuppressed patients (18 IBD, 3 solid organ transplant recipients) were enrolled and compared with 57 age/sex-matched healthy controls. In ARMOR participants, anti-spike IgG GMT increased significantly post-immunization (22,969 to 66,639 EU/mL; 2.9-fold increase, p = 0.001). Healthy controls increased from 54,812 to 129,813 EU/mL (2.4-fold increase; p < 0.001). After baseline adjustment, no significant difference existed between groups at day 28. At 6 months, antibodies waned faster in immunosuppressed subjects. NVX-CoV2601 was well tolerated without IBD flares or organ rejection.

CONCLUSION

NVX-CoV2601 was safe and immunogenic with similar humoral responses compared to healthy controls, making it a viable alternative for immunosuppressed patients.

Для цитирования: Vattoth Ahamed Lazim, Hayney Mary S, Forati Amir Masoud, Warren Brandy, Kalkeri Raj, Cai Miranda R, Cai Zhaohui, Zhu MingZhu, Cloney-Clark Shane, Plested Joyce S, Parajuli Sandesh, Caldera Freddy. Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.. Vaccine. 2026. DOI: 10.1016/j.vaccine.2026.128208.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.